Belkis Kaplan, PharmD Resident

Fixed-dose rasburicase (3-6 mg) achieves urate control comparable to weight-based dosing while streamlining care and reducing costs in cancer-associated TLS prophylaxis.

Digitoxin reduces primary composite vs placebo in HFrEF, with no statistically significant effect on individual components of all-cause mortality or first heart failure-related hospitalization.

Reduced-dose apixaban maintains efficacy with less bleeding for extended CAT prophylaxis, reinforcing NCCN’s preexisting guidance in intermediate to high-risk cancer patients.